ReviewEvidence-based complementary and alternative medicine : eCAM2022
Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.
Review in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- WGCNA-Based Identification of Hub Genes and Key Pathways Involved in Obesity.Molecular biotechnology · 2026Article
- Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery.International journal of molecular sciences · 2025Review
- Herbal Nanoformulations for Diabetes: Mechanisms, Formulations, and Clinical Impact.Current diabetes reviews · 2025Review
- Alternative therapeutic strategies in diabetes management.World journal of diabetes · 2024Review
- Dietary phenolic compounds as promising therapeutic agents for diabetes and its complications: A comprehensive review.Food science & nutrition · 2024Review
- Genetic and Transcriptomic Background of Oxidative Stress and Antioxidative Therapies in Late Complications of Type 2 Diabetes Mellitus: A Systematic Review.Antioxidants (Basel, Switzerland) · 2024Review
- Translational Research on Bee Pollen as a Source of Nutrients: A Scoping Review from Bench to Real World.Nutrients · 2023Article
- Nanoformulations for the Delivery of Dietary Anthocyanins for the Prevention and Treatment of Diabetes Mellitus and Its Complications.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Article
- Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications.Antioxidants (Basel, Switzerland) · 2023Review
- Dietary Polyphenols as Natural Inhibitors of α-Amylase and α-Glucosidase.Life (Basel, Switzerland) · 2022Review
- The Utilization of Physiologically Active Molecular Components of Grape Seeds and Grape Marc.International journal of molecular sciences · 2022Review
- Polyphenols Targeting Oxidative Stress in Spinal Cord Injury: Current Status and Future Vision.Oxidative medicine and cellular longevity · 2022Review
- Article
- Evaluation of in vivo Antidiabetic, Antidyslipidemic and in vitro Anti-Oxidant Activity of Extract and Solvent Fractions ofJournal of experimental pharmacology · 2022Article
- Efficacy and Safety of Gegen Qinlian Decoction for Pediatric Diarrhea: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a fatal metabolic disorder, and its prevalence has escalated in recent decades to a greater extent. Since the incidence and severity of the disease are constantly increasing, plenty of therapeutic approaches are being considered as a promising solution. Many dietary polyphenols have been reported to be effective against diabetes along with its accompanying vascular consequences by targeting multiple therapeutic targets. Additionally, the biocompatibility of these polyphenols raises questions about their use as pharmacological mediators. Nevertheless, the pharmacokinetic and biopharmaceutical properties of these polyphenols limit their clinical benefit as therapeutics. Pharmaceutical industries have attempted to improve compliance and therapeutic effects. However, nanotechnological approaches to overcome the pharmacokinetic and biopharmaceutical barriers associated with polyphenols as antidiabetic medications have been shown to be effective to improve clinical compliance and efficacy. Therefore, this review highlighted a comprehensive and up-to-date assessment of polyphenol nanoformulations in the treatment of diabetes and vascular consequences.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.